Merck Sues to Stop Generic NuvaRing
Merck is accusing Warner Chilcott, a division of Actavis, of violating its patent on NuvaRing. Actavis has announced that it might file an application to market a generic version of the NuvaRing in 2018, the year its patent expires.
Actavis hopes to be the first to market a generic version of the female contraceptive. It wants to be the first to market a generic ring because it could be the only company selling a generic version for 180 days, thanks to a "first applicant" clause, the company noted. It is unknown how long courts will take to rule on the lawsuit.
It is easy to see why Merck is fighting so hard to protect the NuvaRing patent -- it is expected to make $664 million from annual sales of the vaginal hormonal contraceptive ring, according to Bloomberg.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.